Table 2

Virus strain used in assay
		A/NC/99 (H1N1)			A/WI/05 (H3N2)			BM/04
		Response			Response			Response
Test^a	Vaccine	pre	post	rate^b	pre	post	rate	pre	post	rate
HI	LAIV	54	80	6	57	77	13	11	12	0
	TIV	135	160	19	104	258	31	24	38	19
MI	LAIV	11	14	31^c	11	13	38^c	ND	ND	ND
	TIV	10	13	38^c	14	19	44^c	ND	ND	ND
Neutralizing	LAIV	197	234	56	133	150	50	128	161	38
	TIV	263	363	75	101	223	94	182	382	81

^aSerologic tests are described in Methods and Materials: the HI assay follows a standard protocol; the NI assay followed a miniaturized thiobarbituric acid method to quantify sialic acid; the neutralization assay followed a novel “AVINA” protocol in which NA activity is used as an end-point.
^bResponse rate is the percent of individuals in each group that had a statistically significant increase in titer: for HI assays this is a 4-fold increase; for NI this is a 2-fold increase; for neutralizing antibodies this is a statistically significant increase in the IC50 determined by non-linear regression.
^cPreviously reported [20].

Table 2: Serologic responses following LAIV and TIV. Geometric mean titers of HI, NI and neutralizing (AVINA) antibodies are shown for all individuals in each vaccine group (n=16) before and after vaccination (pre and post), and percent of individuals with a significant increase in titer (response rate) following immunization with LAIV and TIV.